Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease

Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher disease (GD), and is the first available plant cell–expressed recombinant therapeutic protein. Herein, we report long‐term safety and efficacy results of taliglucerase alfa in treatment‐naïve adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimran, Ari, Durán, Gloria, Mehta, Atul, Giraldo, Pilar, Rosenbaum, Hanna, Giona, Fiorina, Amato, Dominick J., Petakov, Milan, Muñoz, Eduardo Terreros, Solorio‐Meza, Sergio Eduardo, Cooper, Peter A., Varughese, Sheeba, Chertkoff, Raul, Brill‐Almon, Einat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074246/
https://www.ncbi.nlm.nih.gov/pubmed/27174694
http://dx.doi.org/10.1002/ajh.24369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074246/
https://www.ncbi.nlm.nih.gov/pubmed/27174694
http://dx.doi.org/10.1002/ajh.24369

Ejemplares similares